1. Home
  2. Research
  3. Research Groups
  4. Biomarkers and Personalized Approach to Cancer Group (BioPAC)

Biomarkers and Personalized Approach to Cancer Group (BioPAC)

Search for publications

Only original articles, editorials, guidelines.

  • Pérez-Ruiz A, Ruiz-Cañas L, Batres S, Ferreras-Martín R, Pinto-Díez C, Yagüe B, Pérez-Morgado MI, Sacristán S, Ruz-Caracuel I, Páez SC, Sanchez-Perez I, González VM, Alcalá S, Martín ME, Sainz B Jr.

    Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells.

    JOURNAL OF BIOMEDICAL SCIENCE . 33(1): .

    [doi:10.1186/s12929-026-01275-6]

  • Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta-Gallego D, Morales-Cacho L, Álvarez R, Sun P, Rosas-Perez B, Barrero R, Jiménez-Parrado S, López-García A, San Roman M, López-Gil JC, Drosten M, Sainz B Jr, Musteanu M, Caleiras E, Dusetti N, Poli V, Sánchez-Bueno F, Guerra C, Barbacid M.

    A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 123(23): .

    [doi:10.1073/pnas.2610708123]

  • He J, Sabroso-Lasa S, Coscia C, López de Maturana E, Alonso L, Lawlor RT, Carrato A, Alvarez Gallego R, Iglesias M, Molero X, Michalski C, Perea J, Löhr M, O'Rorke MA, Barberá VM, Tardon A, Farré A, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress TM, Greenhalf W, Sharp L, Moreno-Oya A, Costello E, Kleeff J, Kong B, Mora J, O'Driscoll D, Scarpa A, Ye W, Real FX, Malats N.

    A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.

    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION . 35(6): 1009-1018.

    [doi:10.1158/1055-9965.EPI-25-1601]

  • Losa F, Etxaniz O, Giménez A, Gomila P, Iglesias L, Longo F, Nogales E, Sánchez A, Soler G, Fernández I.

    SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025).

    Clinical & Translational Oncology . 28(5): 1610-1623.

    [doi:10.1007/s12094-026-04241-8]

  • Abal-Sanisidro M, Ruiz-Cañas L, Batres-Ramos S, Blanco MG, García-Bermejo ML, García-Fernández J, Rodríguez-Cobo L, López-Higuera JM, Sainz B Jr, de la Fuente M.

    Evaluation of Self-Illuminating Nanoconjugates Against Pancreatic Ductal Adenocarcinoma.

    International Journal of Nanomedicine . 21: 545161-545161.

    [doi:10.2147/IJN.S545161]

  • Tiwary K, Lahusen A, Inaas S, Beitzinger B, Schmid R, Harms M, Hauff S, Arnold F, Walter K, Alcala S, Hahn S, Heßmann E, Kleger A, Azoitei N, Seufferlein T, Sainz B Jr, Münch J, Lindén M, Hermann PC.

    A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma.

    Scientific Reports . 16(1): .

    [doi:10.1038/s41598-026-48584-2]

  • Yaringaño J, Mirallas O, Navarro V, Gómez-Puerto D, Velilla G, Vaz MÁ, Gorria T, Martínez-Monino Á, Hernández A, Aguado M, Di Muzio A, Valbuena DL, Ruiz-Pace F, González M, Martínez-García M, Villacampa G, Balaña C, Carles J, Dienstmann R, Pineda E, Sepúlveda JM, Vieito M.

    Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort.

    Cancer Medicine . 15(4): .

    [doi:10.1002/cam4.71825]

  • Loukopoulos E, Fabra D, Melones-Herrero J, Matesanz AI, Viciana C, Platero-Prats AE, Sánchez-Pérez I, Quiroga AG.

    Structural features and antibacterial activity of Ni(II) thiosemicarbazones in a zirconium metal-organic framework composite.

    DALTON TRANSACTIONS . 55(13): 5130-5138. Number of citations: 2

    [doi:10.1039/d5dt03008k]

  • Stelmach R, Lorenzen S, Ettrich TJ, Longo FR, Chibaudel B, Greil R, Perwög M, Larcher-Steiner J, Jäger D, Lordick F, Stocker G, Haag GM.

    Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

    ESMO Gastrointestinal Oncology . 11: 100297-100297.

    [doi:10.1016/j.esmogo.2025.100297]

  • Mirallas O, Ruiz-Pace F, Velilla G, Gómez-Puerto D, Gorria T, Yaringaño J, Martínez-Monino Á, López-Valbuena D, Vaz MA, Hernandez A, Martínez-Saez E, Sorolla MA, Castro-Henriques M, Bardaji JL, Di Muzio A, Gallego O, Martínez-García M, Domenech M, Carles J, Balaña C, Pineda E, Dienstmann R, Sepúlveda JM, Vieito M.

    Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study.

    npj Precision Oncology . 10(1): 46-46. Number of citations: 1

    [doi:10.1038/s41698-025-01247-3]

  • Starling N, Elez E, Strickler JH, Benson A, Oki E, Mendez G, Ferreiro R, Lau YL, Kawazoe A, Tian M, Campbell N, Cohen DN, Edwards K, Stjepanovic N, Seligmann JF.

    A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.

    Future Oncology . 22(2): 137-145. Number of citations: 6

    [doi:10.1080/14796694.2025.2606910]

  • Bakirdögen D, Görgülü K, Xin J, Richter L, Alcalá S, Ruiz-Cañas L, Dai C, Frank KJ, Wu N, Diakopoulos KN, Ozturk H, Demircioglu D, Peschke K, Ranjan R, Fusco F, Martinez-Useros J, Fernandez-Aceñero MJ, Chhabra NF, López-Gil JC, Ai J, Ruess DA, Kaya-Aksoy E, Schmidt F, Kohlmann L, Berninger A, Yangin H, Schicktanz F, Steiger K, Demir IE, Schmid RM, Reichert M, Adli M, Lesina M, Sainz B Jr, Algül H.

    c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT.

    Molecular Cancer . 25(1): 16-16. Number of citations: 3

    [doi:10.1186/s12943-025-02486-5]

  • Liaki V, Barrambana S, Kostopoulou M, Lechuga CG, Zamorano-Dominguez E, Acosta D, Morales-Cacho L, Álvarez R, Sun P, Rosas-Perez B, Barrero R, Jiménez-Parrado S, López-García A, San Roman M, López-Gil JC, Drosten M, Sainz B Jr, Musteanu M, Caleiras E, Dusetti N, Poli V, Sánchez-Bueno F, Guerra C, Barbacid M.

    A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 122(49): . Number of citations: 12

    [doi:10.1073/pnas.2523039122]

  • Salazar J, Arranz MJ, Martin-Broto J, Serra M, Palmerini E, Martínez-García J, Juan-Ribelles A, Andion M, Martinez-Trufero J, Gutiérrez G, Echebarria-Barona A, Vaz-Salgado MA, Regueiro A, Alvarez R, Valverde C, Luna P, Blay P, Sebio A.

    VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

    Pharmaceuticals . 18(12): .

    [doi:10.3390/ph18121855]

  • Vaz-Salgado MÁ, Del Barco S, Sepúlveda JM, Alonso M, Pineda E, Balana C, Martínez-García M, Gironés R.

    Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial

    Nature Communications . 17(1): 86-86. Number of citations: 2

    [doi:10.1038/s41467-025-66747-z]

  • Xue N, Sabroso-Lasa S, Merino X, Munzo-Beltran M, Schuurmans M, Olano M, Estudillo L, Ledesma-Carbayo MJ, Liu J, Fan R, Hermans JJ, van Eijck C, Malats N.

    A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study

    GUT . 74(12): 2024-2034. Number of citations: 1

    [doi:10.1136/gutjnl-2024-334237]

  • Urbanova M, Viol F, Ruiz-Cañas L, Koniaris E, Saksis R, Batres-Ramos S, Earl J, Kataki A, Buocikova V, Burikova M, Cihova M, Rojikova L, Makovicky P, Matuskova M, Kohl Y, Riedmayer A, Makova M, Baciak L, Gogola D, Rogoza O, Rovite V, Sainz B Jr, Smolkova B, Schrader J.

    Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma

    CANCER LETTERS . 634: 218033-218033. Number of citations: 2

    [doi:10.1016/j.canlet.2025.218033]

  • Rabadan R, Filip I, Balsells J, López de Maturana E, Langtry A, Alonso L, Sabroso-Lasa S, Moreno-Oya A, Gómez-Rubio P, Molina-Montes E, Márquez M, Milne R, Alfaro A, Lobato T, Estudillo L, Real FX, Malats N, Scarpa A, Lawlor R, Beghelli S, Alvarez-Gallego R, Cubillo A, Hidalgo M, Peinado P, Salas I, Rodríguez Pascual J, Carrato A, Earl J, Caminoa A, Guillén-Ponce C, Rodríguez-Garrote M, Longo-Muñoz F, Ferreiro R, Pachón V, Vaz MÁ, Muñoz M, Iglesias M, Ilzarbe L, Álvarez-Urturi C, Bessa X, Bory F, Márquez L, Poves I, Burdío F, Grande L, Gimeno J, Molero X, Guarner L, Balcells J, Salcedo M, Merino X, Michalski CW, Esposito I, Kleeff J, Kong B, Mota C, Löhr MJ, Huang J, Verbeke C, Ye W, Yu J, Loinaz C, Perea J, Rodríguez-Peralto JL, Teijo A, Peláez P, Farré A, Mora J, Martín M, Artigas V, Guarner C, Sancho FJ, Concepción M, Ramón Y Cajal T, Szafranska J, O'Rorke M, Murray L, Cantwell M, Barberà VM, Gallego J, Tardón A, Barneo L, Rodriguez-Suarez MM, Domínguez-Muñoz E, Pazos Y, Lozano A, Luaces M, Blanco-Antona F, Sayagués Manzano JM, Gutiérrez Troncoso ML, Orfao de Matos A, Muñoz-Bellvís L, Gress TM, Buchholz M, Neesse A, Greenhalf W, Costello E, Crnogorac-Jurcevic T, Kocher HM, Bhattacharya S, Abraham AT, Ennis D, Dowe T, Radon T, O'Driscoll D, Sharp L.

    Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis

    Nature Communications . 16(1): 10769-10769. Number of citations: 2

    [doi:10.1038/s41467-025-65811-y]